Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Eastern Regional Medical Center
Study ID
NCT02496286
Phase
PHASE1
Status
Terminated

Conditions

  • Malignant Ascites

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks for up to six weeks, or a maximum of three treatments.

Key Dates

Start date
Jun 30, 2015
Status verified
Jul 2017
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Eligible patients requiring paracentesis for symptom control

Primary Outcome Measure

Radiographic Improvement [ Time Frame: 14 days (+/-4 days) ]

Locations (1)

FacilityCityStateZIP
Eastern Regional Medical CenterPhiladelphiaPennsylvania19124

Find similar trials in Philadelphia, PA

By research site
Eastern Regional Medical Center· Philadelphia, PA

Related Studies